Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

Ikegame, Satoshi; Siddiquey, Mohammed Nure Alam; Hung, Cheng‐Chieh; Haas, Griffin; Brambilla, Luca; Oguntuyo, Kasopefoluwa Y.; Kowdle, Shreyas; Vilardo, Ariel Esteban; Edelstein, Alexis; Perandones, Claudia; Kamil, Jeremy P.; Lee, Benhur

doi:10.1101/2021.03.31.21254660

Cited by 15 publications

(8 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emergence of new SARS-CoV-2 variants is starting to threaten our pool of vaccines, as data suggest that not every immunogen will work equally well against them over time (22,23). This concern is greater for vaccines available in developing countries.…”

Section: Discussionmentioning

confidence: 99%

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Marc¹,

Álvarez-Paggi²,

Polack³

2021

Journal of Clinical Investigation

View full text Add to dashboard Cite

Efforts to best protect the world from SARS-CoV-2 as variants emerge and despite limited vaccine supply are ongoing. One strategy that may maximize vaccine coverage and expedite immunization campaigns involves providing single mRNA vaccine doses to individuals with previous COVID-19. In this issue of the JCI two independent studies, Levi and Azzolini et al. and Mazzoni and Lauria et al., explored vaccine responses in individuals previously infected with the virus. Levi, Azzolini and colleagues used multilinear regression models to correlate exposure and symptoms, with antibody response to the vaccine. Mazzoni, Lauria and colleagues characterized B cell and T cell kinetics in whole blood after one and two doses of vaccine in health care workers with and without previous infection. Both studies indicate that one vaccine dose may sufficiently protect individuals who have recovered from COVID-19. Implementing a single dose mRNA vaccine protocol in previously symptomatic individuals may facilitate and expedite immunization campaigns.

show abstract

Section: Discussionmentioning

confidence: 99%

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Marc¹,

Álvarez-Paggi²,

Polack³

2021

Journal of Clinical Investigation

View full text Add to dashboard Cite

show abstract

“…In an Argentine cohort study, among 707 health professionals, a response rate of Sputnik V was 96.6% while 71.3% reported one or more events supposedly attributed to vaccination and immunization during follow-up at 72 hours post first dose [163]. In studies regarding the efficacy of Sputnik V on variants of concern, it was observed that rAd26 and rAd5 successfully neutralized spike protein of B.1.1.7, showed moderate efficacy against variants with E484K mutation (also resistant to CoronaVac), and failed to neutralize spike protein of B.1.351 [164,165]. Currently, the vaccine is in use in In a study, the efficacy of BBV152 against two newly developed strains of coronavirus was assessed [167].…”

Section: Sinopharm (Inactivated Virus Vaccine)mentioning

confidence: 99%

Counting on COVID-19 vaccine: Insights into the current strategies, progress and future challenges

Kandimalla¹,

Chakraborthy²,

Vallamkondu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus (SARS-CoV-2) in late 2019 and its subsequent substantial spread, produced coronavirus disease 2019 (COVID-19) pandemic worldwide. Given its unprecedented infectivity and pathogenicity, COVID-19 pandemic had a devastating impact on human health and its clinical management. It led to development and speedy trials of several vaccine candidates against SARS-CoV-2 at an exceptional pace; as a result, several COVID-19 vaccines were made commercially available in the 2021 first half. Although, several COVID-19 vaccines showed promising results, crucial in-sights into their epidemiology, protective mechanism and propensity of reinfection are not largely reviewed. In the present report, we provided insights into the prospects of vaccination against COVID-19 and assessed diverse vaccination strategies including DNA, mRNA, protein subunits, vector-based, live attenuated, and inactivated whole/viral particle-based vaccines, imi-tating COVID-19 infection. Next, we reviewed major aspects of various available vaccines ap-proved by the WHO and by local administration to use against COVID-19. Moreover, we com-prehensively assessed the success of these approved vaccines and also their untoward effects in-cluding the possibility of reinfection. We also provided an update on the vaccines that are under development and could be the promising candidate. Conclusively, we provided insights into the COVID-19 vaccine epidemiology, their potency and propensity for SARS-CoV-2 reinfection, while a careful review of their current status, strategies, success and future challenges was also presented.

show abstract

“…[21,22] Earlier in the month of April the study of Argentina shows that people had those antibodies in their body after the completion of both the doses of Sputnik-V which are effective against the UK variant B.1.1.7 variant. [21,25]…”

Section: Covaxin Vaccine-bharat Biotech Manufactured This Vaccine In Collaboration With Icmr (Indian Council Of Medical Researchmentioning

confidence: 99%

A Review on Vaccination Drive for COVID-19 in India

Yukta

Patil

2021

Int J Health Sci Res

View full text Add to dashboard Cite

The Covid-19 pandemic is destructing the whole world rapidly and also results in changing the order of human life. Various strategies and efforts are being applied by health experts to fight against the pandemic. Various vaccines are developed by researchers of different countries. The aim for developing the vaccines is to produce Herd immunity i.e. to resist the spread of SARS-CoV-2 virus. 8-12 years are required for the development of vaccine in normal circumstances but in emergency like Covid-19 pandemic vaccines get ready in 10 months by various methods like viral vector vaccines, mRNA based vaccines, inactivated vaccines. In India only three vaccines i.e. Covaxin, Covishield, and Sputnik-V get the Emergency Use Authorisation (EUA) from the drug controller general of India (DCGI). Vaccines vary in their efficacy that’s why only few vaccines get the emergency approval across the globe. These vaccines also show mild to moderate and in some case rare adverse effects. Key words: Pandemic, Vaccines, Covid-19, Herd immunity, Adverse effects.

show abstract

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

Cited by 15 publications

References 73 publications

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine

Counting on COVID-19 vaccine: Insights into the current strategies, progress and future challenges

A Review on Vaccination Drive for COVID-19 in India

Contact Info

Product

Resources

About